

ASX Release**Successful completion of Entitlement Offer**

The Board of TALi Digital Limited (ASX: TD1, "TALi" or "the Company") is pleased to announce the successful completion of its fully underwritten 1 for 7 non-renounceable entitlement offer ("Entitlement Offer") of new fully paid ordinary shares ("New Shares") in TALi as announced to the ASX on Friday, 18 March 2022.

The Entitlement Offer closed on Friday, 8 April 2022 and raised a total of \$916,829.57 (before costs) at \$0.011 per New Share.

TALi received valid applications totalling 83,347,965 New Shares, representing a take-up rate of approximately 54.4%, consisting of 41,607,909 additional New Shares taken up by eligible shareholders in excess of their entitlement under the Top-Up Facility. Non-executive Directors who hold shares in TALi took up their entitlements in full.

The Entitlement Offer was fully underwritten by Taylor Collison Limited. Approximately 69,752,044 New Shares not taken up under the Entitlement Offer (including under the Top-Up Facility) will be allocated to the underwriter and/or sub-underwriters in accordance with the underwriting arrangements ("Shortfall Shares").

New Shares issued under the Entitlement Offer will rank equally in all respects with existing shares. New Shares are expected to be allotted on Tuesday, 19 April 2022, with holding statements to be despatched on the same day. Shortfall Shares will be issued shortly thereafter in accordance with the underwriting arrangements.

If you have any questions in relation to the Entitlement Offer, please contact the Share Registry on 1300 284 664 (within Australia) or +61 2 9698 5414 (outside Australia).

Release authorised by:

The Board of TALi Digital Limited

CONTACT**Corporate**

Sue MacLeman
Chair
TALi Digital
0437 211 200
investors@talidigital.com

Investor Relations

Paul McKeon
Investor Relations Manager
TALi Digital
1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.